Ashvattha Therapeutics, a clinical-stage nanomedicine company, announced it will present breakthrough data on two novel radiotracers at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting from June 21-24, 2025, in New Orleans. The presentations will showcase the company's ability to tune its hydroxyl dendrimer platform to achieve selective uptake in neuroinflammation in humans and in tumor-associated macrophages in cancer animal models.
Targeting Neuroinflammation with Flurimedrimer
The company will present findings on flurimedrimer, a novel nanomedicine radiotracer that selectively targets activated microglia in the human brain. This development supports Ashvattha's neurology pipeline by providing a precision imaging tool for neuroinflammation. Dr. Farshad Moradi from Stanford University will present the data on Sunday, June 22, 2025, during the Molecular Targeting Probes session.
Advancing Cancer Imaging Through Macrophage Targeting
Ashvattha's second radiotracer is designed to selectively target tumor-associated macrophages, potentially advancing precision imaging capabilities in oncology. Jeff Cleland, PhD, CEO of Ashvattha Therapeutics, will present this data on Monday, June 23, 2025, during a poster session. The development represents a significant step forward in cancer imaging technology by focusing on the tumor microenvironment.
Platform Technology and Clinical Applications
Ashvattha Therapeutics is advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells only in regions of inflammation. The company's targeted nanomedicine approach seeks to redefine precision medicine across multiple therapeutic areas including ophthalmology, neurology, oncology, and inflammation.
The hydroxyl dendrimer platform's versatility allows for selective targeting of different cell types involved in inflammatory processes, as demonstrated by the two distinct radiotracers being presented at SNMMI. This platform technology enables the development of both diagnostic imaging agents and therapeutic interventions for conditions characterized by inflammation.
Company Background
Founded by Kannan Rangaramanujam, Sujatha Kannan, and Jeff Cleland, Ashvattha Therapeutics was incubated by Natural Capital. The clinical-stage company focuses on developing nanomedicine therapeutics that can traverse tissue barriers and selectively target activated cells in inflammatory regions, representing a novel approach to precision medicine across multiple therapeutic areas.
